Rafael Holdings (RFL)

Rafael Holdings (RFL) – FDA

May 24, 2022 11:06 AM EMA Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613 for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer (RFL)
Nov 3, 2021 09:03 AM EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613 (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma (RFL)
Oct 28, 2021 08:02 AM
Oct 28, 2021 07:02 AM
Aug 25, 2021 10:02 AM
Jul 1, 2021 08:01 AM
Jun 29, 2021 11:01 AM
Dec 15, 2020 09:02 AM
Oct 29, 2020 09:51 AM
Oct 27, 2020 09:07 AM
Oct 20, 2020 09:03 AM
Aug 6, 2020 10:14 AM
Jul 22, 2020 05:52 AM
May 7, 2020 09:05 AM
Apr 28, 2020 09:12 AM
Mar 24, 2020 09:05 AM
Jan 21, 2020 09:12 AM
Jan 14, 2020 09:05 AM
Oct 24, 2019 09:05 AM
Oct 17, 2019 09:06 AM
Oct 8, 2019 09:03 AM
Sep 19, 2019 09:05 AM
Sep 17, 2019 09:45 AM
Aug 1, 2019 10:18 AM
Jul 18, 2019 10:47 AM
Jan 10, 2019 08:04 AM
Jan 9, 2019 08:09 AM
Jan 8, 2019 08:07 AM
Nov 29, 2018 09:15 AM